The link between FOXJ1 expression level in bladder carcinoma and tumor recurrence Retraction in /10.3892/ol.2018.8920

Liang,Bing; He,Xinwei; Shang,Donghao; Tian,Ye; Liu,Zongwen

doi:10.3892/ol.2017.7504

The link between FOXJ1 expression level in bladder carcinoma and tumor recurrence

Retraction in: /10.3892/ol.2018.8920

Authors:
- Bing Liang
- Xinwei He
- Donghao Shang
- Ye Tian
- Zongwen Liu
View Affiliations

Affiliations: Department of Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China , Department of Infection, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China , Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China , Department of Radiotherapy, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: November 29, 2017 https://doi.org/10.3892/ol.2017.7504
Pages: 1483-1486
Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We studied the expression level of FOXJ1 in bladder epithelial carcinoma and its relation to clinical features and tumor recurrence. From January 2014 to June 2015, 66 patients with bladder epithelial carcinoma were enrolled in this study and their tumor and para‑carcinoma tissue samples were collected. FOXJ1 positive expression rate was evaluated using immunohistochemical staining, and FOXJ1 mRNA expression level was measured by RT‑PCR. RT‑PCR and immunohistochemistry results showed that FOXJ1 expression level in tumor samples was significantly lower than that in para‑carcinoma tissue samples. The median survival time in patients with positive expression of FOXJ1 was significantly longer than that of patients with negative expression of FOXJ1. We also showed that FOXJ1 expression level was negatively correlated with neoplasm staging and tumor recurrence rate. We concluded that FOXJ1 was expressed in low quantities in bladder epithelial carcinoma, which was closely correlated with the biological characteristics of the tumor. FOXJ1 expression presents a promising application prospect for further exploration of the specific biological mechanism of FOXJ1 in regulating the occurrence and development of bladder epithelial carcinoma. FOXJ1 may be used as a new marker for early diagnosis and prediction of recurrence.

View Figures

View References

1	Sha N, Xie L, Chen T, Xing C, Liu X, Zhang Y, Shen Z, Xu H, Wu Z, Hu H, et al: Impact of lymphovascular invasion on recurrence and progression rates in patients with pT1 urothelial carcinoma of bladder after transurethral resection. Onco Targets Ther. 8:3401–3406. 2015.PubMed/NCBI
2	Schlegel JU, Pipkin GE, Nishimura R and Duke GA: Studies in the etiology and prevention of bladder carcinoma. J Urol. 101:317–324. 1969. View Article : Google Scholar : PubMed/NCBI
3	Caburet S, Vaiman D and Veitia RA: A genomic basis for the evolution of vertebrate transcription factors containing amino Acid runs. Genetics. 167:1813–1820. 2004. View Article : Google Scholar : PubMed/NCBI
4	Chen HW, Huang XD, Li HC, He S, Ni RZ, Chen CH, Peng C, Wu G, Wang GH, Wang YY, et al: Expression of FOXJ1 in hepatocellular carcinoma: Correlation with patients' prognosis and tumor cell proliferation. Mol Carcinog. 52:647–659. 2013. View Article : Google Scholar : PubMed/NCBI
5	Venugopalan SR, Amen MA, Wang J, Wong L, Cavender AC, D'Souza RN, Akerlund M, Brody SL, Hjalt TA and Amendt BA: Novel expression and transcriptional regulation of FoxJ1 during oro-facial morphogenesis. Hum Mol Genet. 17:3643–3654. 2008. View Article : Google Scholar : PubMed/NCBI
6	Major ML, Lepe R and Costa RH: Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol Cell Biol. 24:2649–2661. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, Miyachi Y, Tsukada T and Sakaguchi S: Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature. 446:685–689. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ma RY, Tong TH, Leung WY and Yao KM: Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1. Methods Mol Biol. 647:113–123. 2010. View Article : Google Scholar : PubMed/NCBI
9	Postnikoff SD, Malo ME, Wong B and Harkness TA: The yeast forkhead transcription factors fkh1 and fkh2 regulate lifespan and stress response together with the anaphase-promoting complex. PLoS Genet. 8:e10025832012. View Article : Google Scholar : PubMed/NCBI
10	Laoukili J, Kooistra MR, Brás A, Kauw J, Kerkhoven RM, Morrison A, Clevers H and Medema RH: FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 7:126–136. 2005. View Article : Google Scholar : PubMed/NCBI
11	Myatt SS and Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859. 2007. View Article : Google Scholar : PubMed/NCBI
12	Karadedou CT, Gomes AR, Chen J, Petkovic M, Ho KK, Zwolinska AK, Feltes A, Wong SY, Chan KY, Cheung YN, et al: FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene. 31:1845–1858. 2012. View Article : Google Scholar : PubMed/NCBI
13	Lin L, Spoor MS, Gerth AJ, Brody SL and Peng SL: Modulation of Th1 activation and inflammation by the NF-kappaB repressor Foxj1. Science. 303:1017–1020. 2004. View Article : Google Scholar : PubMed/NCBI
14	Demircan B, Dyer LM, Gerace M, Lobenhofer EK, Robertson KD and Brown KD: Comparative epigenomics of human and mouse mammary tumors. Genes Chromosomes Cancer. 48:83–97. 2009. View Article : Google Scholar : PubMed/NCBI
15	Lu T and Stark GR: Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle. 3:1114–1117. 2004. View Article : Google Scholar : PubMed/NCBI
16	Siu MK, Wong ES, Kong DS, Chan HY, Jiang L, Wong OG, Lam EW, Chan KK, Ngan HY, Le XF, et al: Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene. 32:3500–3509. 2013. View Article : Google Scholar : PubMed/NCBI